| Transcript | Q2 FY26 earnings call transcript |
| 2026-08-05 | Press release | Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance |
| 2026-08-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-05 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-16 | Press release | Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026 |
| 2026-07-01 | Press release | Caris Life Sciences Launches Caris Detect, the World's Most Sensitive and Comprehensive Multi-Cancer Early Detection Blo |
| 2026-06-16 | Press release | Caris Life Sciences Announces Dual Listing on NYSE Texas |
| 2026-06-08 | Press release | Caris Life Sciences Announces Share Repurchase Program |
| 2026-06-05 | 8-K | Form 8-K, Item 5.07 |
| 2026-05-26 | Press release | Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensiv |
| 2026-05-15 | Press release | Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehens |
| 2026-05-11 | Press release | Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Over |
| 2026-05-08 | Press release | Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood‑Based Testing Auth |
| 2026-05-08 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-07 | Press release | Caris Life Sciences Reports First Quarter 2026 Financial Results |
| 2026-05-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-04-29 | Press release | Caris Life Sciences Publishes Study Validating Caris AI Insights for Temozolomide Benefit in Glioblastoma Patients |
| 2026-04-24 | Press release | Caris Life Sciences to Present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Glob |
| 2026-04-23 | Proxy | Definitive proxy statement |
| 2026-04-17 | Press release | Caris Precision Oncology Alliance Welcomes UCSF Helen Diller Family Comprehensive Cancer Center |
| 2026-04-08 | Press release | Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition |
| 2026-04-02 | 8-K | Form 8-K, Item 1.01 |
| 2026-03-31 | Press release | Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Dete |
| 2026-03-26 | Press release | Caris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung |
| 2026-03-03 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-28 | Transcript | Q4 FY25 earnings call transcript |
| 2026-02-26 | Deck | Caris Fourth Quarter and Full Year 2025 Financial Results Conference Presentation |
| 2026-02-26 | Press release | Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook |
| 2026-02-26 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-23 | Press release | Caris Life Sciences to Participate in the TD Cowen 46th Annual Health Care Conference |
| 2026-02-09 | Press release | Caris Life Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26 |
| 2026-01-28 | Press release | Caris Life Sciences' Real-World Data Uncovers Metastatic Breast Cancer Patient Responses and Resistance to Trastuzumab D |
| 2026-01-12 | Deck | 44th Annual J.P. Morgan Healthcare Conference Presentation |
| 2026-01-12 | Press release | Caris Life Sciences Partners with Everlywell to Launch Caris' Forthcoming MCED Assay, Caris Detect |
| 2026-01-12 | Press release | Caris Life Sciences Announces Preliminary Fourth Quarter and Full Year 2025 Results |
| 2026-01-12 | 8-K | Form 8-K, Item 2.02 results |
| 2026-01-05 | Press release | Caris Life Sciences to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 2025-11-05 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-05 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-10-30 | 8-K | Form 8-K, Item 3.03 |